<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-36 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-36</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-36</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <p><strong>Paper ID:</strong> paper-224e65a93a19fc49f8b1be24f3f8bb7370b83728</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/224e65a93a19fc49f8b1be24f3f8bb7370b83728" target="_blank">Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease.</a></p>
                <p><strong>Paper Venue:</strong> Biochimica et Biophysica Acta</p>
                <p><strong>Paper TL;DR:</strong> Cis and trans conformation-specific antibodies are developed to provide the first direct evidence that tau exists in distinct cis and trans conformations and that Pin1 accelerates its cis to trans conversion, thereby protecting against tangle formation in AD.</p>
                <p><strong>Cost:</strong> 0.016</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e36.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e36.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Cancer–Alzheimer inverse</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Inverse association between cancer and Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Multiple epidemiologic studies report an inverse comorbidity between cancer and Alzheimer's disease (AD); the review proposes Pin1 dysregulation (overactive in many cancers, downregulated/inactivated in AD) as a major molecular explanation linking the two in opposite directions, together with other shared pathways (p53, Wnt, oxidative stress, metabolism, inflammation).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Multiple common cancers (general discussion; specific examples include lung, prostate, breast and colon cancers; also breast cancer models driven by Ras/Neu are discussed in animal studies)</td>
                        </tr>
                        <tr>
                            <td><strong>neurodegenerative_disease</strong></td>
                            <td>Alzheimer's disease (sporadic and familial AD discussed; MCI mentioned as early stage)</td>
                        </tr>
                        <tr>
                            <td><strong>correlation_type</strong></td>
                            <td>inverse correlation</td>
                        </tr>
                        <tr>
                            <td><strong>epidemiological_evidence</strong></td>
                            <td>Multiple cohort and population studies cited reporting reduced incidence of AD among cancer survivors and reduced incidence of cancer among AD patients: Roe et al. (longitudinal memory cohort) HR for development of cancer among those with AD = 0.39 (95% CI 0.21–0.74); CHS: prevalent cancer at baseline associated with lower risk of probable AD HR = 0.57 (95% CI 0.36–0.90); CHS: prevalent AD associated with fewer cancer hospitalizations HR = 0.31 (95% CI 0.12–0.86); Framingham Heart Study: diagnosis with cancer decreased risk of AD HR = 0.67 (95% CI 0.47–0.97), incident AD decreased risk of subsequent cancer HR = 0.29 (95% CI 0.26–0.58). The review notes these associations are not explained by survival bias or detection bias and are observed both before and after diagnoses.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Central proposed mechanism is dysregulation of the prolyl isomerase Pin1 operating in opposite directions: Pin1 is commonly overexpressed/activated in many cancers where it promotes oncogenic pathways (stabilizes/activates Cyclin D1, c-Jun, β-catenin, NF-κB, promotes centrosome amplification and genomic instability), whereas Pin1 is down-regulated, oxidized, phosphorylated or sequestered in AD brain leading to failure to isomerize phosphorylated pSer/Thr–Pro motifs on tau (e.g., pT231) and APP (Thr668-Pro) from pathogenic cis conformations back to trans, thereby promoting tau dysfunction, aggregation (neurofibrillary tangles), pathogenic APP processing and Aβ accumulation; additional mechanisms contributing to opposite phenotypes include differential regulation of p53 (DNA-damage response/tumor suppression vs neuronal maintenance), Wnt signaling, GSK-3 and CDK-mediated hyperphosphorylation of tau/APP, telomere maintenance, oxidative stress responses and metabolic/inflammatory pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>genes_involved</strong></td>
                            <td>PIN1 (prolyl isomerase) — upregulated/activated in many cancers, downregulated/inactivated in AD; TP53 — tumor suppressor, its interaction with Pin1 preserves p53 function after DNA damage; BRCA1 — suppresses Pin1 activity; DAPK1 — phosphorylates and inhibits Pin1; genes in Wnt pathway (e.g., CTNNB1/β-catenin) — Pin1 regulates β-catenin turnover; CCND1 (Cyclin D1) — expression stabilized/induced by Pin1; TRF1 — telomere binding protein whose stability is regulated by Pin1. The review also references transcriptomic meta-analysis that identifies PIN1, WNT and P53 among genes differentially regulated in cancer vs AD.</td>
                        </tr>
                        <tr>
                            <td><strong>proteins_involved</strong></td>
                            <td>Pin1 (peptidyl-prolyl cis-trans isomerase) — central; Tau (microtubule-associated protein) — pT231 cis conformation is pathogenic when not isomerized by Pin1; APP (amyloid precursor protein) — Thr668-Pro phosphorylation yields cis form that favors amyloidogenic processing when Pin1 inactive; Aβ (amyloid-beta) — downstream toxic peptide from APP; GSK-3β and CDK5 — kinases that hyperphosphorylate tau and APP; Cyclin D1, c-Jun, β-catenin, NF-κB — oncogenic effectors modulated by Pin1; p53 protein — stabilized and functionally modulated by Pin1; TRF1 — telomere protein regulated by Pin1; MCL-1 and gephyrin are mentioned as neuronal Pin1 targets.</td>
                        </tr>
                        <tr>
                            <td><strong>pathways_involved</strong></td>
                            <td>Proline-directed phosphorylation/isomerization signaling (Pin1-dependent), cell cycle regulation (Cyclin D1, CDKs), Wnt/β-catenin signaling, p53-dependent DNA damage response, GSK-3 signaling, CDK5 signaling, proteasomal degradation/turnover pathways, telomere maintenance, oxidative stress response, inflammatory/immune pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>cellular_process</strong></td>
                            <td>Opposing balance between cell proliferation (cycling cells) and long-term somatic maintenance/survival in post-mitotic neurons; processes include cell proliferation vs apoptosis, mitotic coordination and centrosome duplication, protein phosphorylation/dephosphorylation, cis–trans isomerization of phosphorylated pSer/Thr–Pro motifs, protein aggregation and impaired degradation (tau/APP), telomere maintenance, oxidative stress responses.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_evidence</strong></td>
                            <td>Molecular and animal model data summarized: Pin1 knockout (Pin1-/-) mice develop age-dependent neurodegeneration with hyperphosphorylated tau and pathogenic APP processing leading to Aβ accumulation and premature aging phenotypes, while showing resistance to tumorigenesis; Pin1-deficient mice are almost completely resistant to breast cancers driven by Ras or Neu and resistant when p53 is deleted in models — indicating reduced tumorigenesis when Pin1 absent; Pin1 overexpression in postnatal neurons protects against age-dependent neurodegeneration in mice; conformation-specific cis/trans pT231 tau antibodies detect early pathogenic cis-tau species in MCI/AD human brain and show Pin1 accelerates cis→trans conversion; promoter polymorphisms: a Chinese PIN1 promoter polymorphism increasing Pin1 expression associates with ~3-year delayed AD onset; other variants reducing Pin1 expression associate with reduced cancer risk (meta-analysis); biochemical studies: Pin1 binds APP at Thr668-Pro and accelerates cis→trans conversion, favoring non-amyloidogenic processing and increased APP turnover; Pin1 inhibits GSK-3 activity, limiting hyperphosphorylation of tau and APP.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_examples</strong></td>
                            <td>Heterogeneity exists: in a study of renal cell carcinoma, Pin1 appeared to suppress tumor growth (Teng et al. cited), and some effects vary by mouse genetic background. Vascular dementia and stroke are reported to have increased cancer diagnosis (not inverse), indicating the inverse relationship is not universal across neurodegenerative/neurological disorders. The review emphasizes cancer is heterogeneous and Pin1's effect may depend on cancer type/history.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review article synthesizing epidemiological cohort studies, molecular biology, genetic association and animal-model experimental studies (epidemiologic studies, animal model studies, molecular/cellular biology experiments, genetic association/meta-analytic evidence cited).</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Pin1 dysregulation — overexpression/activation in many cancers and down-regulation/inactivation in AD — provides a coherent molecular explanation for the observed inverse epidemiologic association between cancer and Alzheimer's disease, linking shared pathways that are deregulated in opposite directions.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease.", 'publication_date_yy_mm': '2015-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e36.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vascular dementia–cancer relation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Positive association between vascular dementia/stroke and cancer (counterexample to inverse comorbidity)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The review notes that unlike Alzheimer's disease, vascular dementia and stroke are associated with an increased risk of cancer diagnosis, indicating the inverse comorbidity is specific rather than universal across neurodegenerative/neurological disorders.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Not specified to type; general increased cancer diagnoses reported</td>
                        </tr>
                        <tr>
                            <td><strong>neurodegenerative_disease</strong></td>
                            <td>Vascular dementia and stroke</td>
                        </tr>
                        <tr>
                            <td><strong>correlation_type</strong></td>
                            <td>positive association (increased cancer diagnosis)</td>
                        </tr>
                        <tr>
                            <td><strong>epidemiological_evidence</strong></td>
                            <td>Cited cohort data (Roe et al., and CHS referenced in the review) report that people with vascular dementia and stroke actually have an increased risk of cancer diagnosis compared with non-vascular dementia groups; exact numeric HRs for this specific comparison are not provided in the text of the review.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Not mechanistically detailed in this review; invoked to show specificity of inverse association and to argue against detection or survival bias explanations (different neurodegenerative diseases show different associations with cancer), implying disease-specific biology (e.g., vascular pathology vs protein-misfolding/neurodegeneration) underlies differing comorbidity patterns.</td>
                        </tr>
                        <tr>
                            <td><strong>genes_involved</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>proteins_involved</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>pathways_involved</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>cellular_process</strong></td>
                            <td>Not detailed for this contrast; used as an epidemiologic counterexample to show the inverse relation is specific to AD rather than generalized to all dementias.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_evidence</strong></td>
                            <td>Epidemiologic cohort observations cited; no molecular/animal experimental data provided in the review specifically linking vascular dementia/stroke to cancer mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_examples</strong></td>
                            <td>This positive association is presented as a contrast to the cancer–AD inverse; highlights that inverse comorbidity is not uniform across neurological diseases.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Mentioned from cohort/epidemiological studies cited in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Vascular dementia and stroke show increased cancer diagnoses in cited studies, indicating the inverse association between cancer and neurodegeneration is disease-specific (not a general feature of all dementias).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease.", 'publication_date_yy_mm': '2015-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e36.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Pin1 tumor-suppressive exception</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Context-dependent (tumor-suppressive) role of Pin1 in renal cell carcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Although Pin1 is described as oncogenic in many cancers, the review notes at least one study where Pin1 suppressed tumor growth in renal cell carcinoma, illustrating that Pin1's role in cancer can be context- and tissue-dependent.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Renal cell carcinoma (specific study cited where Pin1 showed tumor-suppressive activity)</td>
                        </tr>
                        <tr>
                            <td><strong>neurodegenerative_disease</strong></td>
                            <td>Alzheimer's disease (contrast discussed elsewhere in review)</td>
                        </tr>
                        <tr>
                            <td><strong>correlation_type</strong></td>
                            <td>mixed / context-dependent (Pin1 generally promotes cancer but can be tumor-suppressive in specific cancer types)</td>
                        </tr>
                        <tr>
                            <td><strong>epidemiological_evidence</strong></td>
                            <td>No epidemiologic statistics provided for this specific exception in the review; it cites the existence of a study reporting Pin1 tumor-suppressive activity in renal cell carcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Not elaborated in the review; mentioned to note complexities and that Pin1's net effect depends on tumor type/genetic background.</td>
                        </tr>
                        <tr>
                            <td><strong>genes_involved</strong></td>
                            <td>PIN1 (context-dependent role)</td>
                        </tr>
                        <tr>
                            <td><strong>proteins_involved</strong></td>
                            <td>Pin1 (in this context proposed to have tumor-suppressive rather than tumor-promoting activity)</td>
                        </tr>
                        <tr>
                            <td><strong>pathways_involved</strong></td>
                            <td>Not specified in detail for this exception in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>cellular_process</strong></td>
                            <td>Indicates that Pin1 modulation of cell-cycle/signaling can have differing consequences depending on cellular context and tumor-specific pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_evidence</strong></td>
                            <td>Single-cited study (Teng et al.) reporting Pin1 acts as a tumor suppressor in renal cell carcinoma; no further mechanistic or replication data presented in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_examples</strong></td>
                            <td>This is itself a counterexample to the generalization that Pin1 uniformly promotes cancer; the review also cites variability by mouse genetic background for Pin1 effects.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Mention of an original experimental study (molecular/oncology study) in the literature; here reported as a counterexample in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Pin1's role in cancer is not universally oncogenic; at least one study reports tumor-suppressive activity in renal cell carcinoma, underscoring context dependence and caution for Pin1-targeting therapies.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease.", 'publication_date_yy_mm': '2015-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders <em>(Rating: 2)</em></li>
                <li>Alzheimer disease and cancer <em>(Rating: 2)</em></li>
                <li>Cancer linked to Alzheimer disease but not vascular dementia <em>(Rating: 2)</em></li>
                <li>Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study <em>(Rating: 2)</em></li>
                <li>Infect occurrence of cancer and Alzheimer disease: a population-based incidence study <em>(Rating: 1)</em></li>
                <li>Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses <em>(Rating: 2)</em></li>
                <li>Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration <em>(Rating: 2)</em></li>
                <li>The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production <em>(Rating: 2)</em></li>
                <li>Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer’s disease <em>(Rating: 2)</em></li>
                <li>Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>